Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART)

Abstract Homocysteine has been proposed as a risk factor for atherosclerosis. The association between plasma total homocysteine (tHcy) concentration and carotid atherosclerosis has not been thoroughly studied in high-risk populations with vascular disease. For this study, carotid atherosclerosis was assessed by measurements of carotid intima-media thickness (IMT) and plaque calcification in 923 patients with vascular disease or diabetes. Associations with tHcy and plasma folate concentrations were examined. The mean and single maximum carotid IMT were 1.27 ± 0.34 mm and 2.41 ± 0.83 mm, respectively. The mean segment plaque calcification score was 27.8%. tHcy correlated with mean (r = 0.13; p < 0.001) and single maximum (r = 0.12; p < 0.001) carotid IMT. There was a progressive increase in mean and single maximum carotid IMT across quartiles of tHcy (p < 0.0001 for trend). These associations were no longer significant after adjusting for other CV risk factors. A trend towards an inverse association between plasma folate and mean max carotid IMT was found in both univariate and multivariable analyses. However, the plaque calcification score increased across quartiles of tHcy (p < 0.01) and decreased across quartiles of plasma folate concentrations (p < 0.05) after multiple adjustments. In conclusion, in high-risk individuals, tHcy and low folate concentrations were only weakly associated with carotid IMT. In contrast, we found an independent association with the plaque calcification score, a measure of more advanced atherosclerosis. The effect of tHcy lowering on carotid atherosclerosis and stroke prevention warrants further investigation.

[1]  Xiping Xu,et al.  Efficacy of folic acid supplementation in stroke prevention: a meta-analysis , 2007, The Lancet.

[2]  K. Reynolds,et al.  Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. , 2006, JAMA.

[3]  D. Wald,et al.  Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence , 2006, BMJ : British Medical Journal.

[4]  Joseph Loscalzo,et al.  Homocysteine trials--clear outcomes for complex reasons. , 2006, The New England journal of medicine.

[5]  S. Yusuf,et al.  Homocysteine lowering with folic acid and B vitamins in vascular disease. , 2006, The New England journal of medicine.

[6]  Per Magne Ueland,et al.  Homocysteine lowering and cardiovascular events after acute myocardial infarction. , 2006, The New England journal of medicine.

[7]  Christopher M Kramer,et al.  Carotid artery calcification on CT may independently predict stroke risk. , 2006, AJR. American journal of roentgenology.

[8]  J. Spence.  Homocysteine: call off the funeral. , 2006, Stroke.

[9]  S. Yusuf,et al.  Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial. , 2006, The Canadian journal of cardiology.

[10]  H. Bang,et al.  Vitamin Intervention for Stroke Prevention Trial: An Efficacy Analysis , 2005, Stroke.

[11]  Seymour Glagov,et al.  B-mode ultrasonographic characterization of carotid atherosclerotic plaques in symptomatic and asymptomatic patients. , 2005, Journal of vascular surgery.

[12]  R. Vollandt,et al.  Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12. , 2005, Atherosclerosis.

[13]  R. Abbate,et al.  Homocysteine-lowering therapy and carotid intima-media thickness in renal transplant recipients. , 2005, Transplantation proceedings.

[14]  J. Spence,et al.  Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products , 2005, Canadian Medical Association Journal.

[15]  M. Bots,et al.  Low concentrations of folate, not hyperhomocysteinemia, are associated with carotid intima-media thickness. , 2005, Atherosclerosis.

[16]  L. Smeeth,et al.  For Personal Use. Only Reproduce with Permission from Elsevier Ltd Homocysteine and Stroke: Evidence on a Causal Link from Mendelian Randomisation , 2022 .

[17]  M. Bots,et al.  Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. , 2004, Atherosclerosis.

[18]  L. Chambless,et al.  Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. , 2004, JAMA.

[19]  D. Wald,et al.  Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis , 2002, BMJ : British Medical Journal.

[20]  Petra Verhoef,et al.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.

[21]  Per Magne Ueland,et al.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. , 2002, JAMA.

[22]  D. Cole,et al.  Declining Rate of Folate Insufficiency Among Adults Following Increased Folic Acid Food Fortification in Canada , 2002, Canadian journal of public health = Revue canadienne de sante publique.

[23]  S. Yusuf,et al.  Effects of Ramipril and Vitamin E on Atherosclerosis: The Study to Evaluate Carotid Ultrasound Changes in Patients Treated With Ramipril and Vitamin E (SECURE) , 2001, Circulation.

[24]  E. Falk,et al.  Homocysteine and atherothrombosis , 2001, Lipids.

[25]  R. Williams,et al.  Plasma homocysteine and its association with carotid intimal-medial wall thickness and prevalent coronary heart disease: NHLBI Family Heart Study. , 2000, Atherosclerosis.

[26]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[27]  J. Beilby,et al.  Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) , 1999, Circulation.

[28]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[29]  R. Ross,et al.  Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. , 1983, Circulation research.

[30]  R. Ross,et al.  Homocystinemia. Vascular injury and arterial thrombosis. , 1974, The New England journal of medicine.

[31]  K. Mccully.  Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. , 1969, The American journal of pathology.